Oral fluid testing proves comparative accuracy to urinalysis in detecting drug use

December 11, 2003

A recently published study in the December issue of Drug and Alcohol Dependence indicates that the use of oral fluid analysis may be an effective alternative to urinalysis in detecting drug use in a opiate treatment setting. Gerald A. Bennett and Eleanor Davies from the Addictions Service, Dorset HealthCare NHS Trust and Peter Thomas from Dorset Research and Development Support Unit, Poole Hospital NHS Trust, Bournemouth University studied the use of rapid oral testing to assess accuracy in detecting drugs of abuse. The study examined specificity and sensitivity of oral screening as a viable alternative to urinalysis, which is more invasive and an often defrauded method.

One hundred and fifty-seven subjects with known drug problems were tested. The subjects were seeking treatment for substance abuse and were tested periodically to monitor continued drug use. They were screened using three methods for use of opiates, methadone, benzodiazepines, and amphetamines. The subjects each submitted to a laboratory urinalysis, and rapid screenings of both oral fluids and urine. The results of the study showed that the subjects in a treatment setting could be administered an oral fluid analysis as an alternative to a urinalysis with similar accuracy in detecting opiate or methadone use. However, the oral screening was significantly less effective at detecting the presence of benzodiazepines than the urinalysis. The screening for amphetamines was discontinued because of a very small number of subjects using those drugs. The ease of administration of the oral fluid test makes it an attractive alternative to urinalysis, but with several limitations. Substances in saliva are only detectable for 12 to 24 hours after consumption, a shorter time period than in urine. Testing for other drugs of abuse, such as marijuana was not evaluated. Further clinical testing is needed to determine if it is effective in detecting drug use in a non-treatment setting. Nevertheless, the method offers an attractive alternative to expensive and invasive urinary testing.
-end-
For more information, please contact:
Dr Gerald Bennett
Consultant Clinical Psychologist
Addiction Services
Dorset HealthCare NHS Trust
16-18 Tower Road
Bournemouth
BH1 4LP
United Kingdom
Telephone: +44 1202 443174
Fax: +44 1202 395116
email: gerald.bennett@dorsethc-tr.swest.nhs.uk

© 2003 Drug and Alcohol Dependence. All rights reserved. Unauthorized use prohibited.

About Drug and Alcohol Dependence
Drug and Alcohol Dependence (www.elsevier.com/locate/drugalcdep), published by Elsevier, is the official journal of the College on Problems of Drug Dependence (www.cpdd.org), the largest and oldest organization for the scientific study of drug dependence.

Drug and Alcohol Dependence publishes original research, scholarly reviews, commentaries, and policy analyses in the area of drug, alcohol and tobacco use and dependence. The hope of its editors is to promote mutual understanding of the many facets of drug abuse to the benefit of all investigators involved in drug and alcohol research, and to facilitate the transfer of scientific findings to successful treatment and prevention practices.

The information contained in Drug and Alcohol Dependence is not a substitute for medical advice or treatment, and the Journal recommends consultation with your physician or healthcare professional.

About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, the company publishes more than 1,800 journals and 2,200 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (www.sciencedirect.com) and MD Consult (http://www.mdconsult.com/) bibliographic databases, online reference works and subject specific portals.

Elsevier (www.elsevier.com) is a global company headquartered in Amsterdam, The Netherlands and has offices worldwide. The company is part of Reed Elsevier Group plc (www.reedelsevier.com), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Elsevier

Related Alcohol Dependence Articles from Brightsurf:

Three genes predict success of naltrexone in alcohol dependence treatment
Of patients who seek treatment for alcohol use disorder, 60% to 80% relapse within a year.

In mice, alcohol dependence results in brain-wide remodeling of functional architecture
Using novel imaging technologies, researchers produce first whole-brain atlas at single-cell resolution, revealing how alcohol addiction and abstinence remodel neural physiology and function in mice.

Years of education may impact drinking behavior and risk of alcohol dependence
Higher educational attainment -- spending more years in education -- may impact people's drinking behavior and reduce their risk of alcohol dependence, according to a study published in Molecular Psychiatry.

Potential novel biomarker for alcohol dependence
Specific molecules (small noncoding microRNAs or miRNAs) found in saliva may be able to predict alcohol dependence as biomarkers.

Alcohol dependence, psychiatric disorders share genetic links
An international team of researchers has identified a gene that regulates how quickly the body metabolizes alcohol as a key risk factor for alcohol dependence.

Opioid use may affect treatment for alcohol dependence
New research indicates that opioid misuse and the use of cannabis and other drugs may compromise the effectiveness of treatments for alcohol use disorder.

No magic pill to cure alcohol dependence yet
A new study published by the scientific journal Addiction has found no reliable evidence for using nalmefene, naltrexone, acamprosate, baclofen or topiramate to control drinking in patients with alcohol dependence or alcohol use disorder.

Drug used for alcohol dependence might also treat stuttering, suggest researchers
Baclofen, a drug that has recently been used to treat alcohol dependence despite not officially being licensed for this condition, might also help stop stuttering, suggest researchers in the journal BMJ Case Reports.

Surprising brain change appears to drive alcohol dependence
A new study led by scientists at The Scripps Research Institute (TSRI) could help researchers develop personalized treatments for alcoholism and alcohol use disorder.

Prescribing of baclofen for alcohol dependence 'should be reconsidered'
The drug baclofen has received high visibility as a possible breakthrough treatment for alcohol dependence.

Read More: Alcohol Dependence News and Alcohol Dependence Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.